Figures & data
Figure 1 Forest plot of the HAM-D17 total score by subgroups: difference between venlafaxine ER treatment group and the placebo group in the adjusted mean change from baseline at Week 8 with 95% CIs (FAS, LOCF, ANCOVA model).
![Figure 1 Forest plot of the HAM-D17 total score by subgroups: difference between venlafaxine ER treatment group and the placebo group in the adjusted mean change from baseline at Week 8 with 95% CIs (FAS, LOCF, ANCOVA model).](/cms/asset/e4af8da3-0e8c-4e8f-9e4d-f5db3834d2a6/dndt_a_146428_f0001_b.jpg)
Figure 2 Forest plot of the HAM-D6 score by subgroups: difference between venlafaxine ER treatment group and the placebo group in the adjusted mean change from baseline at Week 8 with 95% CIs (FAS, LOCF, ANCOVA model).
![Figure 2 Forest plot of the HAM-D6 score by subgroups: difference between venlafaxine ER treatment group and the placebo group in the adjusted mean change from baseline at Week 8 with 95% CIs (FAS, LOCF, ANCOVA model).](/cms/asset/54996440-a239-4f3c-a120-d4ffa3301efa/dndt_a_146428_f0002_b.jpg)
Figure 3 Forest plot of the MADRS total score by subgroups: difference between venlafaxine ER treatment group and the placebo group in the adjusted mean change from baseline at Week 8 with 95% CIs (FAS, LOCF, ANCOVA model).
![Figure 3 Forest plot of the MADRS total score by subgroups: difference between venlafaxine ER treatment group and the placebo group in the adjusted mean change from baseline at Week 8 with 95% CIs (FAS, LOCF, ANCOVA model).](/cms/asset/c56a6428-12eb-4732-a86f-be882cbb5806/dndt_a_146428_f0003_b.jpg)
Figure 4 Adjusted mean change from baseline at Week 8 with 95% CIs by duration of MDD (≤22 months/>22 months) in each efficacy endpoint (FAS, LOCF, ANCOVA model).
![Figure 4 Adjusted mean change from baseline at Week 8 with 95% CIs by duration of MDD (≤22 months/>22 months) in each efficacy endpoint (FAS, LOCF, ANCOVA model).](/cms/asset/9d520c21-7ea6-4289-a0d3-6729232eb8a6/dndt_a_146428_f0004_b.jpg)
Figure 5 Adjusted mean change from baseline in each efficacy endpoint at Week 8 with 95% CIs by duration of MDD (A) <12 months/≥12 months, and (B) <48 months/≥48 months (FAS, LOCF, ANCOVA model).
![Figure 5 Adjusted mean change from baseline in each efficacy endpoint at Week 8 with 95% CIs by duration of MDD (A) <12 months/≥12 months, and (B) <48 months/≥48 months (FAS, LOCF, ANCOVA model).](/cms/asset/cf6cb1ae-9e01-4292-9ed1-b65fd0e47886/dndt_a_146428_f0005_b.jpg)
Table 1 Demographic and disease characteristics by duration of MDD (≤22 months/>22 months) (FAS)
Figure 6 Adjusted mean change from baseline at Week 8 with 95% CIs by HAM-D17 total score at baseline (total score ≤22/total score >22) in each efficacy endpoint (FAS, LOCF, ANCOVA model).
![Figure 6 Adjusted mean change from baseline at Week 8 with 95% CIs by HAM-D17 total score at baseline (total score ≤22/total score >22) in each efficacy endpoint (FAS, LOCF, ANCOVA model).](/cms/asset/0665709c-d45c-4803-971e-cfea02ef3bc1/dndt_a_146428_f0006_b.jpg)
Figure 7 Adjusted mean change from baseline at Week 8 with 95% CIs by history of previous depressive episodes (0 [single episode]/≥1 [recurrent episodes]) in each efficacy endpoint (FAS, LOCF, ANCOVA model).
![Figure 7 Adjusted mean change from baseline at Week 8 with 95% CIs by history of previous depressive episodes (0 [single episode]/≥1 [recurrent episodes]) in each efficacy endpoint (FAS, LOCF, ANCOVA model).](/cms/asset/2468e920-b6cd-4a7b-9685-d9acef9cab7c/dndt_a_146428_f0007_b.jpg)
Figure 8 Adjusted mean change from baseline at Week 8 with 95% CIs by duration of current depressive episode (≤6.6 months/>6.6 months) in each efficacy endpoint (FAS, LOCF, ANCOVA model).
![Figure 8 Adjusted mean change from baseline at Week 8 with 95% CIs by duration of current depressive episode (≤6.6 months/>6.6 months) in each efficacy endpoint (FAS, LOCF, ANCOVA model).](/cms/asset/cb291074-02b7-4766-9a38-48ba420b985a/dndt_a_146428_f0008_b.jpg)